研究单位：[1]Beijing InnoCare Pharma Tech Co., Ltd.[2]The First Affiliated Hospital of Anhui Medical University,Hefei,Anhui,China,230022[3]Peking University Third Hospital,Beijing,Beijing,China,100191[4]The First Affiliated Hospital of Chongqing Medical University,Chongqing,Chongqing,China,400016[5]Xinqiao Hospital, the Second Affiliated Hospital of Army Military Medical University,Chongqing,Chongqing,China,400037[6]Fujian Medical University Union Hospital,Fuzhou,Fujian,China,350001[7]The First Affiliated Hospital of Xiamen University,Xiamen,Fujian,China,361003[8]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China,510055[9]The Fourth Hospital of Hebei Medical University,Shijiazhuang,Hebei,China,050010[10]Nanyang City Center Hospital,Nanyang,Henan,China,473005[11]Henan Provincial People's Hospital,Zhengzhou,Henan,China,463599[12]Henan Cancer Hospital,Zhenzhou,Henan,China,450003[13]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430011[14]Union Hospital Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430022[15]The Second Xiangya Hospital, Central South University,Changsha,Hunan,China,410012[16]Hunan Cancer Hospital,Changsha,Hunan,China,410031[17]Jiangsu Province Hospital,Nanjing,Jiangsu,China,210029[18]The First Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330006[19]Bethune First Hospital of Jilin University,Changchun,Jilin,China,130061[20]The Second Hospital of Dalian Medical University,Dalian,Liaoning,China,116023[21]Shengjing Hospital affiliated to China Medical University,Shenyang,Liaoning,China,Liaoning[22]Shandong Cancer Hospital,Jinan,Shandong,China,250117[23]Linyi City Cancer Hospital,Linyi,Shandong,China,276002[24]Huashan Hospital,Shanghai,Shanghai,China,200040[25]The Second Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shanxi,China,710004[26]Sichuan Provincial People's Hospital,Chengdu,Sichuan,China,610072[27]Yibin Second People's Hospital,Yibin,Sichuan,China,644002[28]Tianjin Medical University Cancer Institute and Hospital,Tianjin,Tianjin,China,300181[29]The Affiliated Cancer Hospital of Xinjiang Medical University,Urumqi,Xinjiang Uygur Autonomous Region,China,830000[30]The First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China,650032[31]The First Affiliated Hospital of Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310003
研究目的：
Evaluate the safety, tolerability and pharmacokinetics of ICP-248 in Combination with Orelabrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
